Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant.
NPJ Vaccines
; 6(1): 137, 2021 Nov 18.
Article
en En
| MEDLINE
| ID: mdl-34795290
ABSTRACT
We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Idioma:
En
Revista:
NPJ Vaccines
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos